3379 studies found for:    "Antineoplastic Agents, Alkylating"
Show Display Options
Rank Status Study
1 Active, not recruiting Trial of GVHD Prophylasxis With PTCy or Thymoglobulin in Unrelated SCT
Conditions: Leukemia, Chronic Myeloid;   Myelodysplastic Syndromes;   Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
Interventions: Procedure: Unrelated allogeneic stem cell transplantation;   Drug: Busulfan;   Drug: Fludarabine monophosphate;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Drug: Cyclophosphamide;   Drug: Thymoglobulin
2 Active, not recruiting Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCT
Conditions: Acute Myeloid Leukemia;   Acute Lymphoid Leukemia;   Lymphoma;   Myelodysplastic Syndromes;   Chronic Lymphocytic Leukemia;   Immune System Diseases
Interventions: Drug: Cyclophosphamide;   Drug: Busulfan;   Drug: Fludarabine monophosphate;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Procedure: Allogeneic hematopoietic stem cell transplantation
3 Recruiting Randomized Study of Combination Chemotherapy With or Without Focused Microwave Thermotherapy Before Surgery in Treating Women With Large Breast Cancer Tumors
Condition: Breast Cancer
Interventions: Device: Focused Microwave Thermotherapy;   Drug: Chemotherapy (control)
4 Terminated
Has Results
SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma
Condition: Anaplastic Large Cell Lymphoma
Interventions: Drug: Cyclophosphamide;   Drug: Doxorubicin hydrochloride;   Drug: vincristine sulfate;   Drug: prednisone;   Drug: SGN-30
5 Completed A Study of Trabectedin in Patients With Advanced Ovarian Cancer
Conditions: Ovarian Neoplasms;   Endocrine Gland Neoplasms;   Neoplasms by Site;   Neoplasms;   Ovarian Diseases;   Adnexal Diseases;   Genital Diseases, Female
Interventions: Drug: Trabectedin;   Drug: Dexamethasone
6 Completed A Study on the Effect of Chemotherapy Combined With Anti-HIV Drugs in HIV-Positive Patients
Condition: HIV Infections
Interventions: Drug: Nelfinavir mesylate;   Drug: Lamivudine;   Drug: Filgrastim;   Drug: Stavudine;   Drug: Cyclophosphamide
7 Completed A Study of ET-743 (Trabectedin) in Patients With Advanced Breast Cancer
Conditions: Breast Neoplasms;   Neoplasms;   Neoplasms by Site;   Breast Diseases;   Skin Diseases
Intervention: Drug: ET743
8 Recruiting Chidamide Plus R-CHOP in Elderly DLBCL
Condition: Diffuse Large B-cell Lymphoma
Interventions: Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Epirubicin;   Drug: Vincristine;   Drug: Prednisone;   Drug: Chidamide
9 Recruiting Bendamustine Plus Subcutaneous Rituximab in Patients With Diffuse Large B-cell Lymphoma
Condition: Diffuse Large B Cell Lymphoma
Intervention: Drug: bendamustine, rituximab
10 Recruiting Reduced Chemotherapy in Low Risk DLBCL
Condition: Diffuse Large B-cell Lymphoma
Interventions: Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Epirubicin;   Drug: Vincristine;   Drug: Prednisone
11 Not yet recruiting Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation
Conditions: Acute Myeloid Leukemia;   Myelodysplastic Syndrome;   Acute Lymphocytic Leukemia
Interventions: Drug: Fludarabine;   Radiation: Fractionated total body irradiation;   Drug: Busulfan;   Drug: Cyclophosphamide;   Radiation: Single dose total body irradiation;   Drug: Melphalan;   Drug: Granulocyte-colony stimulating factor;   Procedure: Stem cell transplant;   Drug: Azacitidine
12 Not yet recruiting Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCL
Conditions: Diffuse Large B Cell Lymphoma;   Primary Mediastinal (Thymic) Large B-cell Lymphoma;   Transformed Indolent Lymphoma;   Recurrent Disease;   Refractory Cancer
Intervention: Drug: Bendamustine 90 mg/m2 IV on Days 1-2, Cycles 1-6
13 Active, not recruiting Decitabine+BUCY vs BUCY Conditioning Regimen for RAEB-1, REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT
Conditions: Myelodysplastic Syndrome;   Allogeneic Hematopoietic Stem Cell Transplantation;   Conditioning
Interventions: Drug: Decitabine;   Drug: Busulfan (BU);   Drug: Cyclophosphamide (CY)
14 Not yet recruiting A Trial of Neoadjuvant Everolimus Plus Letrozole Versus FEC in Women With ER-positive, HER2-negative Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Everolimus;   Drug: Letrozole;   Drug: Fluorouracil;   Drug: Epirubicin;   Drug: Cyclophosphamide
15 Not yet recruiting A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
Condition: Diffuse Large B-Cell Lymphoma
Interventions: Drug: Brentuximab vedotin;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Prednisone
16 Not yet recruiting A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia
Conditions: Lymphoma;   Leukemia, Lymphocytic, Chronic, B-Cell
Interventions: Drug: Durvalumab;   Drug: Lenalidomide;   Drug: Rituximab;   Drug: Ibrutinib;   Drug: Bendamustine
17 Not yet recruiting Effects of Rolapitant on Nausea/Vomiting in Patients With Sarcoma Receiving Multi-Day Highly Emetogenic Chemotherapy (HEC) With Doxorubicin and Ifosfamide Regimen (AI)
Condition: Sarcoma
Interventions: Drug: Rolapitant;   Drug: Fosaprepitant;   Behavioral: Questionnaires;   Drug: Dexamethasone;   Drug: Ondansetron;   Drug: Doxorubicin;   Drug: Mesna;   Drug: Ifosfamide;   Drug: Vincristine
18 Recruiting Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma
Interventions: Drug: Bendamustine;   Drug: Rituximab;   Drug: Cytarabine;   Drug: Pegfilgrastim;   Procedure: Leukapheresis;   Drug: Filgrastim;   Procedure: Autologous stem cell transplant
19 Not yet recruiting Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401)
Condition: Multiple Myeloma
Interventions: Procedure: Tumor Cell Collection;   Procedure: Autologous Stem Cell Transplant;   Drug: Melphalan;   Procedure: Leukapheresis;   Biological: Myeloma vaccine;   Drug: GM-CSF;   Drug: Lenalidomide
20 Not yet recruiting Personalized Natural Killer (NK) Cell Therapy in Cord Blood Transplantation (CBT)
Conditions: Leukemia;   Lymphoma;   Myeloma;   Myeloproliferative Diseases
Interventions: Drug: Busulfan;   Drug: Fludarabine;   Drug: Clofarabine;   Drug: Rabbit ATG;   Radiation: Total Body Irradiation (TBI);   Procedure: Cord Blood Infusions;   Drug: Rituximab;   Drug: Cyclophosphamide;   Procedure: Natural Killer Cell Infusion;   Drug: Melphalan;   Drug: Mesna

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years